B Cell Plasma Cell Differentiation Screening Without Radioactive Assays
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for evaluating B cell-related functions in autoimmune diseases, such as those used in the development of drugs for conditions like systemic lupus erythematosus, are limited by the need for specialized laboratories and expensive equipment, making them inaccessible to common laboratories.
Innovation Solution
A method involving the administration of TLR agonists, interleukins, and tumor necrosis factor family members, such as IL-3, CpG-A, and IFNα, to promote B cell differentiation into plasma cells, which can be performed in standard laboratories without specialized equipment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If the 3H-labeled thymidine method is used to evaluate B cell proliferation, then measurement precision is improved, but device complexity and ease of operation deteriorate due to requiring specialized laboratories and expensive equipment
Solution Approach 1:
The patent replaces the mechanical/physical measurement system (radioactivity detection using scintillation counters and specialized equipment) with a biological measurement system (flow cytometry detecting cellular uptake of labeled thymidine). This substitution eliminates the need for expensive radioactivity measurement equipment while maintaining measurement precision through fluorescent detection capabilities available in standard flow cytometers.
Solution Approach 2:
The patent creates a simplified copy of the radioactivity measurement function using fluorescently labeled thymidine analogs that can be detected by flow cytometry. Instead of measuring radioactive decay, the system copies the functional outcome (quantifying DNA synthesis and cell proliferation) using a different detection modality that is accessible in common laboratories.
2Measurement precision
If the 3H-labeled thymidine method is used, then measurement precision is improved, but ease of operation worsens due to requiring certified laboratories and specialized training
Solution Approach 1:
The patent replaces the complex operational requirements of radioactivity measurement with a simpler fluorescent detection system. Flow cytometry is a standardized technique widely available in immunology laboratories, eliminating the need for specialized radiation safety training and certified laboratory status while preserving the ability to accurately measure cell proliferation.
Solution Approach 2:
The patent uses commercially available fluorescently labeled thymidine analogs that can be stored and handled under standard laboratory conditions, replacing the need for expensive, regulated radioactive isotopes that require special handling, storage, and disposal procedures.
3Measurement precision
If the 3H-labeled thymidine method is used, then measurement precision is improved, but loss of substance worsens due to radionuclide contamination problems
Solution Approach 1:
The patent converts the limitation of fluorescent labels (generally lower signal intensity than radioactive labels) into an advantage by using the stability and non-toxicity of fluorescent compounds. The fluorescent thymidine analogs provide sufficient signal for precise measurement without the contamination and loss problems associated with radioactive decay and environmental degradation of radionuclides.
Solution Approach 2:
The patent uses stable fluorescently labeled compounds that do not decay or contaminate the environment, replacing radioactive isotopes that are subject to decay, contamination, and require special waste disposal procedures. The fluorescent labels remain stable throughout the experiment without generating harmful byproducts.
Data Source
AI summary
The present disclosure provides a method for screening and preparing an immunomodulator. The present disclosure further relates to a use of an immunosuppressant in the treatment of immune-related diseases.